Oral desensitization therapy for peanut allergy induces dynamic changes in peanut‐specific immune responses
Allergy2022Vol. 77(8), pp. 2534–2548
Citations Over TimeTop 10% of 2022 papers
Véronique Bajzik, Hannah A. DeBerg, Nahir Garabatos, Blake J. Rust, Kimberly O’Brien, Quynh‐Anh Nguyen, Colin O’Rourke, Alex Smith, Alex H. Walker, Charlie Quinn, Vivian H. Gersuk, Mary Farrington, David Jeong, Brian P. Vickery, Daniel C. Adelman, Erik Wambre
Abstract
Oral desensitization therapy with AR101 leads to decreased basophil sensitivity to peanut and reshapes peanut-reactive T effector cell responses supporting its potential as an immunomodulatory therapy.
Related Papers
- → Oral Immunotherapy(2023)4 cited
- → Human basophil activation measured by CD63 expression and LTC4 release in IgE-mediated food allergy(1999)134 cited
- → Safety and effectiveness of peanut oral immunotherapy in children under 12 months(2023)3 cited
- → ORAL DESENSITIZATION TO PEANUT USING AR101 PEANUT ORAL IMMUNOTHERAPY IN A ROLL-OVER SAFETY STUDY ARC002(2018)4 cited
- → O055 Immunologic effects of AR101 during characterized oral desensitization immunotherapy (CODIT) for peanut allergy(2016)